ERBB2 and breast cancer: Continuing with the HER2+ BC scenario, Carey et al. determined that the high expression of HER2 amplicon genes was associated with pCR in a multivariate analysis in HER2+ tumors with stage II and III under Paclitaxel + Trastuzumab + Lapatinib treatment in a cohort of 305 patients (OR = 1.35, p < 0.0252).